A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Clinical trial NCT01083615 · TERMINATED
Trial details
- NCT number
- NCT01083615
- Sponsor
- Achieve Life Sciences
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2010-03-01
- Primary completion
- 2013-03-01
- Enrollment
- 14
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.